Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Investments in cancer research and development between 1998 and 2000 has generated 23 million additional healthy years of life and $1.9 trillion of additional social value.  
  • Cancer death rates for all races/ethnicities and both sexes combined decreased by 2.1% per year from 2002-2004, nearly twice the annual decrease of 1.1% per year from 1993-2002.  
  • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.  
  • According to the Pharmaceutical Research and Manufacturers of America, a number of vaccines are being studied that would cause the body’s own immune system to fight cancer after it has…  
  • Following the current path, the colon cancer incidence rate will increase by 31.8% between 2003 and 2023 (447,000 people). If an alternative path is taken, there will be 17.7% (79,000…